#1 Clinical Trials Search in Europe

Micafungin

Micafungin is an antifungal medication being studied in various clinical trials for preventing and treating fungal infections in different patient populations. These trials aim to evaluate its safety, effectiveness, and optimal dosing in groups like children, newborns, and patients with compromised immune systems. The research explores micafungin’s potential in conditions such as invasive candidiasis and as a prophylactic treatment for high-risk patients.

Table of Contents

What is Micafungin?

Micafungin is an antifungal medication used to treat and prevent various fungal infections. It belongs to a class of drugs called echinocandins. Micafungin is also known by its brand name Mycamine and its research code FK463[1][2]. This medication is particularly useful in hospital settings, especially for patients with weakened immune systems who are at risk of developing serious fungal infections.

How Does Micafungin Work?

Micafungin works by inhibiting the production of beta-1,3-glucan, which is an essential component of fungal cell walls[3]. By disrupting the cell wall formation, micafungin effectively stops the growth and spread of fungal infections in the body.

Conditions Treated with Micafungin

Micafungin is used to treat and prevent various fungal infections, including:

  • Invasive Candidiasis: A serious infection caused by Candida fungi that can affect various parts of the body[4]
  • Esophageal Candidiasis: A fungal infection of the esophagus (the tube connecting the mouth to the stomach)[5]
  • Systemic Candidiasis: A widespread Candida infection affecting multiple organs[6]
  • Candida Meningitis: A fungal infection of the membranes covering the brain and spinal cord[6]

Micafungin is also used for antifungal prophylaxis (prevention) in patients at high risk of developing fungal infections, such as those undergoing:

  • Chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS)[7]
  • Hematopoietic stem cell transplantation (HSCT)[8]

How is Micafungin Administered?

Micafungin is administered intravenously (through a vein) in a hospital or clinical setting. It is typically given as an infusion over one hour[9]. The duration of treatment depends on the type and severity of the infection, as well as the patient’s response to the medication.

Dosage Information

The dosage of micafungin varies depending on the patient’s age, weight, and the condition being treated. Some common dosing regimens include:

  • For adults: 100 mg once daily for treatment, or 50 mg once daily for prophylaxis[9]
  • For children: Dosing is typically based on body weight, ranging from 1 mg/kg to 4 mg/kg per day[8]
  • For neonates (newborns): Higher doses of up to 8 mg/kg per day may be used for treatment[6]

It’s important to note that dosing should always be determined by a healthcare professional based on individual patient factors.

Use in Special Populations

Micafungin has been studied in various special populations, including:

  • Neonates: Research is ongoing to determine the optimal dosing and safety of micafungin in newborns[2]
  • Obese patients: Studies are being conducted to understand how obesity affects the concentration of micafungin in the body[1]
  • Patients on extracorporeal membrane oxygenation (ECMO): Research is examining how ECMO affects micafungin levels in the body[4]
  • Intensive Care Unit (ICU) patients: Studies are investigating the pharmacokinetics (how the body processes the drug) of micafungin in critically ill patients[9]

Potential Side Effects

Like all medications, micafungin can cause side effects. Common side effects may include:

  • Nausea and vomiting
  • Diarrhea
  • Headache
  • Fever
  • Abnormal liver function tests

More serious side effects, although rare, may include:

  • Allergic reactions
  • Liver problems
  • Kidney problems
  • Blood disorders

It’s important to report any unusual symptoms to your healthcare provider while taking micafungin[5].

Ongoing Research

Several clinical trials are currently underway to further investigate the use of micafungin in various patient populations and conditions. These studies aim to:

  • Optimize dosing regimens for different patient groups[3]
  • Evaluate the effectiveness of micafungin for antifungal prophylaxis in high-risk patients[10]
  • Assess the safety and efficacy of micafungin in real-world clinical settings[5]
  • Investigate the use of micafungin in combination with other antifungal medications

These ongoing studies will help healthcare providers better understand how to use micafungin most effectively and safely in different patient populations.

Aspect Details
Primary Uses Prevention and treatment of invasive fungal infections, particularly in immunocompromised patients
Patient Populations Neonates, children, adolescents, adults; patients on ECMO, undergoing stem cell transplants, with obesity, in ICUs
Administration Intravenous infusion; dosages vary by study and patient group
Key Objectives Assess safety, efficacy, pharmacokinetics; determine optimal dosing strategies
Safety Monitoring Liver and kidney function, infusion-related reactions, other adverse events
Specific Conditions Invasive candidiasis, Candida meningitis, prophylaxis in high-risk patients
Unique Aspects Exploration of less frequent dosing schedules, use in special populations (e.g., obese patients, those on extracorporeal support)

FAQ

  • What is micafungin used for in these clinical trials? Micafungin is being studied for preventing and treating various fungal infections, particularly in patients with weakened immune systems. It's being tested in conditions like invasive candidiasis, Candida meningitis, and as a preventive measure in patients undergoing stem cell transplants or those in intensive care units.
  • Which patient groups are being studied in these micafungin trials? The trials are focusing on diverse patient groups, including newborns, children, adolescents, and adults. Specific populations include patients on extracorporeal membrane oxygenation (ECMO), those undergoing stem cell transplants, individuals with obesity, and patients in intensive care units.
  • How is micafungin administered in these studies? Micafungin is typically administered intravenously (through a vein). The dosage and frequency vary depending on the specific study and patient group, ranging from daily doses to less frequent administration schedules being explored in some trials.
  • What are the main goals of these micafungin clinical trials? The primary objectives include assessing the safety profile of micafungin, determining its effectiveness in preventing and treating fungal infections, evaluating its pharmacokinetics (how the body processes the drug) in different patient groups, and identifying optimal dosing strategies for various populations and conditions.
  • Are there any specific side effects being monitored in these trials? While micafungin is generally considered to have a good safety profile, the trials are monitoring for various adverse events. Special attention is given to potential effects on liver and kidney function, infusion-related reactions, and any other unexpected side effects that may occur during treatment.

Ongoing Clinical Trials on Micafungin

  • Study of fosmanogepix compared to standard antifungal drugs for treating invasive mold infections in adults

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium France Germany Greece Italy +2

  • Study comparing 7-day versus 14-day antifungal treatment for patients with uncomplicated candidemia using fluconazole, anidulafungin, or other medications

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Study for Adults with Very High-Risk T-Cell Acute Lymphoblastic Leukemia Using Daratumumab and a Drug Combination

    Not recruiting

    1 1 1
    Investigated drugs:
    Italy

  • Study Comparing Ibrexafungerp and Fluconazole for Treating Candidemia or Invasive Candidiasis in Patients

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium Bulgaria France Germany Greece Italy +1

  • Study on Avibactam and Drug Combination for Treating Severe Infections in Patients

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Greece

Glossary

  • Micafungin: An antifungal medication belonging to the echinocandin class, used to prevent and treat various fungal infections by inhibiting the production of an essential component of fungal cell walls.
  • Invasive Candidiasis: A serious fungal infection caused by Candida species that can affect the blood, heart, brain, eyes, bones, and other parts of the body.
  • Extracorporeal Membrane Oxygenation (ECMO): A life support technique that provides both cardiac and respiratory support to patients whose heart and lungs are unable to function adequately.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body, which helps in determining appropriate dosing and administration.
  • Prophylaxis: Preventive treatment to stop a disease from occurring, often used in patients at high risk of developing infections.
  • Neutropenia: A condition characterized by an abnormally low count of neutrophils, a type of white blood cell important in fighting infections.
  • Hematopoietic Stem Cell Transplantation: A procedure that replaces damaged or diseased bone marrow with healthy stem cells, often used in treating blood cancers and other disorders.
  • Biofilm: A community of microorganisms that adhere to surfaces and each other, often making infections more difficult to treat.
  • Echinocandin: A class of antifungal drugs that includes micafungin, which work by inhibiting the synthesis of a key component of fungal cell walls.
  • Galactomannan test: A diagnostic test used to detect the presence of certain fungi in the body, particularly Aspergillus species.

References

  1. https://clinicaltrials.gov/study/NCT01090141
  2. https://clinicaltrials.gov/study/NCT00818584
  3. https://clinicaltrials.gov/study/NCT02057289
  4. https://clinicaltrials.gov/study/NCT01666769
  5. https://clinicaltrials.gov/study/NCT03174457
  6. https://clinicaltrials.gov/study/NCT03421002
  7. https://clinicaltrials.gov/study/NCT01200355
  8. https://clinicaltrials.gov/study/NCT01417169
  9. https://clinicaltrials.gov/study/NCT01783379
  10. https://clinicaltrials.gov/study/NCT02127788